FOCUS ON ...
The research activities of the team Ecology and Physiopathology of Intestinal Protozoa (ECOPHIP) aims to improve our knowledge of the epidemiology, circulation and pathogenesis of the intestinal protozoa Blastocystis and Cryptosporidium, which are responsible for several tens of millions of infections each year worldwide, particularly in developing countries. Infection with these parasites can cause digestive disorders, which in the case of Cryptosporidium can be fatal in immunocompromised patients and children. On the other hand, the ECOPHIP team has been able to experimentally demonstrate an association between Cryptosporidium infection and the development of digestive cancers. To carry out its research, ECOPHIP has an integrative approach going from the cell to the population by combining laboratory research and field studies in many countries through a very large network of collaborations. Click here to learn more
Video adapted by Manasi Sawant from the animation Cryptosporidium parvum by DEMCON Nymus 3D for Clevers's lab
RECENT SELECTED PUBLICATIONS
TgAP2IX-5 is a key transcriptional regulator of the asexual cell cycle division in Toxoplasma gondii.
Asma S. Khelifa, Cecilia Guillen Sanchez, Kevin M. Lesage, Ludovic Huot, Thomas Mouveaux, Pierre Pericard, Nicolas Barois, Helene Touzet, Guillemette Marot, Emmanuel Roger et Mathieu Gissot.
Nat Commun (2021)
Plasmodium yoelii Uses a TLR3-Dependent Pathway to Achieve Mammalian Host Parasitism
Keswani T, Delcroix-Genete D, Herbert F, Leleu I, Lambert C, Draheim M, Salome-Desnoulez S, Saliou JM, Cazenave PA, Silvie O, Roland J, Pied S. (2020)
Jahnmatz M etAl. Lancet Infect Dis. (2020)
Jouet A etAl.. Eur Respir J. (2020).
Venugopal K etAl. PLoS Pathog. (2020)
Our Youtube chanel
Third episode in the series dedicated to researching Covid-19. This webinar is moderated by Marie Treibert, science popularizer on the La Boîte à curiosités channel. She questions Sandrine Belouzard, virologist and CNRS researcher, who answers all questions relating to antivirals in the treatment of Covid-19. What is the difference between a vaccine and an antiviral treatment? How does an antiviral work? Who will benefit from it? Do we favor therapeutic repositioning or research for a new drug? Through definitions, a press review and an interview, this webinar takes stock of the subject.
One year after the first cases of COVID-19, researchers of the Center for Infection & Immunity of Lille present the current knowledge on SARS-CoV-2 in the context of a series of conferences organized by the Lille Research Taskforce on COVID-19, in partnership with the Society of Sciences, Agriculture and Arts of Lille.
Researchs against Covid-19 at the Institut Pasteur in Lille.
Coronaviruses, specificities and prospects for treatment by Jean Dubuisson, director of the Center for Infection & Immunity of Lille
More than 60 diseases can be transmitted to humans by rats. Among them, Plague, believed to be a disease of the past, has never been eradicated ...
"While bats are not to blame for everything, they have played a role in the transmission of at least 11 viruses" ...
COVID-19: Jean Dubuisson tells us about ANTI-CoV, a project supported by the FRM